Penumbra, Inc. (PEN)

NYSE | Medical Devices / Thrombectomy
Intro rate Introductory pricing for early customers through June 30 — the same full analysis at a lower rate while we refine delivery.
Free
No email, no account, no signup.
Pulling latest news for Penumbra, Inc.…
Bull
Bear
Preliminary read — single AI model with live web search. The deep report cross-checks four models and more sources.
Intro rate Introductory pricing for early customers through June 30 — the same full analysis at a lower rate while we refine delivery.

Professional stock analysis at introductory pricing. 7-day money-back guarantee — no lock-in.

Want the why behind the signal? Get the deep 4-model report — full bull/bear, dated catalysts, dilution risk, weekly refresh. $4.99 $1.25.
Get the deep 4-model report – $4.99 $1.25
Order analysis – $4.99 $1.25

Professional stock analysis at introductory pricing. 7-day money-back guarantee — no lock-in.

Not satisfied? Get your money back within 7 days — no questions asked.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Exchange
NYSE
Sector
Medical Devices / Thrombectomy
Market Cap
$12.8B
We're already tracking Penumbra, Inc. — here are the latest events we've registered

Recent News

  • Penumbra reported Q1 2026 revenue of $374.8M (+15.6% YoY) with 67.6% gross margin. On May 7, 2026, shareholders approved the merger/acquisition by Boston Scientific (offer ~ $374/share), expected to close in H2 2026 subject to regulatory approvals. After the print, some analysts lowered price targets (e.g., Citi to $350, Evercore ISI to $335).
Want to know how this news affects Penumbra, Inc.? Order the analysis.
Order analysis – $4.99 $1.25

Catalysts

Regulatory decisions ahead of BSX acquisition (H2 2026)

Unlock full catalyst analysis →
Order analysis – $4.99 $1.25
Save hours of research. $4.99 $1.25.
Not satisfied? Get your money back within 7 days — no questions asked.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe

What you get

A complete express analysis — not just a signal. Delivered as a webpage in your account.

  • Signal: BUY / HOLD / SELL — with clear reasoning
  • Sentiment score 1–10 based on news, reports, and market data
  • Risk score 1–10 (dilution, jurisdiction, execution)
  • Bull case: 3–5 specific points with evidence (e.g. "Oversold after panic-reaction to security news, opening a technical bounce setup")
  • Bear case: 3–5 specific risks (e.g. "Extreme uncertainty around the security situation in Sinaloa after tragic events")
  • Upcoming catalysts with dates
  • Sources: news, filings, market data, and investor forums
  • Assessment of dilution risk
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of Penumbra, Inc. will be delivered in the same format.

Sample analyses in the same sector

Click to see what a complete analysis looks like.

Cloetta
CLA B
BUY
Medicover
MCOV B
HOLD
Viaplay Group B
VPLAY B
HOLD
Catena AB (publ)
CATE
HOLD
Super Group (SGHC) Limited
SGHC
BUY
Order analysis – $4.99 $1.25
Not satisfied? Get your money back within 7 days — no questions asked.
Penumbra, Inc. (PEN)
Fresh analysis on demand
Buy express analysis – $4.99 $1.25
The information on this page does not constitute investment advice. AI-generated analyses may contain errors. Always conduct your own research before making investment decisions. Firelda.ai is not responsible for any potential losses.